Quantcast

Latest MGuard(TM) Stories

2011-05-17 07:00:00

TEL AVIV, Israel, May 17, 2011 /PRNewswire/ -- InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer of the MGuard(TM) mesh protective stent system, today announced that it has filed its Form 10-Q for the three months ended March 31, 2011 with the U.S. Securities and Exchange Commission. The Company provided an update on progress year-to-date: Fiscal Year-to-Date Highlights During March and April 2011, InspireMD completed financing transactions totaling $11.1...

2011-05-16 07:00:00

PARIS, May 16, 2011 /PRNewswire/ -- InspireMD, Inc. (OTCBB: NSPR) ("Inspire" or the "Company"), the developer of the MGuard(TM) mesh protective stent system, will partake in the EuroPCR conference this week. MGuard, and the recently launched MGuard Prime, InspireMD's new Cobalt Chromium mesh protective stent system will be on display at booth #P14. Both products feature InspireMD's MicroNet® Mesh Technology, a potentially superior solution for thrombus management in...

2011-05-05 12:00:00

TEL AVIV, Israel, May 5, 2011 /PRNewswire/ -- InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer of the MGuard(TM) mesh protective stent system, announced today that it has been approved by FINRA to have its stock quoted on the Over-the-Counter Bulletin Board (OTCBB) under the symbol "NSPR". In addition, on March 31, 2011, InspireMD concluded a $9.7 million PIPE offering in which (i) it raised approximately $9.0 million of cash and (ii) approximately $0.7 million...

2011-03-02 08:49:00

TEL AVIV, Israel, March 2, 2011 /PRNewswire/ -- InspireMD, developer of the MGuard(TM) net protective stent system, has expanded its MGuard production facilities to meet the steady increase in demand. The driving forces behind the accelerating demand for MGuard include the recent recommendation of the European Society of Cardiology (ESC) mesh-based protection to be considered for PCI of highly thrombotic or SVG lesions. Currently, this type of approved mesh technology is exclusively...

2010-12-17 06:00:00

TEL AVIV, Israel, December 17, 2010 /PRNewswire/ -- InspireMD, developer of the novel MGuard(TM), a combination of a coronary stent merged with an embolic protection specifically designed for Acute MI (AMI) patients, received significant exposure at the ICI, Innovations in Interventional Cardiology, meeting this week in Tel-Aviv. InspireMD presented long-term data, including two years of clinical follow-up, to support the Company's MGuard stent technology. The highlight of the...

2009-09-23 09:41:00

SAN FRANCISCO, September 23 /PRNewswire/ -- InspireMD, developers of MGuard(TM), announced today that the first patient has been enrolled in the Israeli MGuard(TM) Registry. MGuard(TM) was successfully implanted in Natanya, Israel, at the Laniado Hospital Cath Lab, managed by Dr. Yitzhak Herz, the principal investigator for the Registry at this hospital. The Israeli MGuard Registry will enroll 100 'real world' MGuard patients from eight hospitals in Israel. Data from the registry...

2009-05-21 07:46:00

BARCELONA, Spain, May 20 /PRNewswire/ -- InspireMD, Ltd. announced today the completion of enrolment for the MAGICAL trial (MGuard(TM) in Acute Myocardial). The trial was designed to confirm the clinical feasibility, safety and performance of MGuard when used during Primary PCI in STEMI patients. The MAGICAL trial is a multicenter, prospective, single arm, 60 patients study (Principal investigator: Dr. Dariusz Dudek, Jagiellonian University, Krakow, Poland). Primary end-points are...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related